C
Christopher Thomas Brain
Researcher at Novartis
Publications - 41
Citations - 1532
Christopher Thomas Brain is an academic researcher from Novartis. The author has contributed to research in topics: Catalysis & Burgess reagent. The author has an hindex of 17, co-authored 41 publications receiving 1415 citations. Previous affiliations of Christopher Thomas Brain include Astex.
Papers
More filters
Journal ArticleDOI
Novel procedure for the synthesis of 1,3,4-oxadiazoles from 1,2-diacylhydrazines using polymer-supported burgess reagent under microwave conditions
TL;DR: In this article, a novel and efficient means of effecting the cyclodehydration of 1,2-diacylhydrazines to provide 1,3,4-oxadiazoles was reported.
Journal ArticleDOI
An intramolecular palladium-catalysed aryl amination reaction to produce benzimidazoles
TL;DR: In this paper, a novel synthesis of benzimidazoles by a palladium-catalysed intramolecular N-arylation reaction from (o-bromophenyl)amidine precursors is described.
Journal ArticleDOI
An improved procedure for the synthesis of benzimidazoles, using palladium-catalyzed aryl-amination chemistry.
TL;DR: New, improved conditions have been developed and optimized for the synthesis of benzimidazoles by intramolecular palladium-catalyzed aryl-amination chemistry, which has led to a range of these heterocycles being prepared rapidly and in excellent yield.
Patent
Pyrrolopyrimidine compounds as cdk inhibitors
Besong Gilbert,Christopher Thomas Brain,Brooks Clinton A,Miles Congreve,Claudio Dagostin,He Guo,Hou Ying,Howard Steven,Li Yue,Yipin Lu,Paul N. Mortenson,Troy Smith,Sung Moo,Steven John Woodhead,Wrona Wojciech,Bharat Lagu +15 more
TL;DR: In this article, the disclosed compounds relate to treatments and therapies for protein kinase-associated disorders and are useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Proceedings ArticleDOI
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
Sunkyu Kim,Alice Loo,Rajiv Chopra,Giordano Caponigro,Alan Huang,Sadhna Vora,Sudha Parasuraman,Steve Howard,Nicholas Keen,William R. Sellers,Christopher Thomas Brain +10 more
TL;DR: Given the role of CDK4/6 downstream of other oncogenic driver mutations, LEE011 shows single agent activity in melanomas with activating mutations of BRAF or NRAS, and in breast cancers with intact estrogen receptor and/or activating aberrations of PIK3CA/Her-2.